Illinois, USA-based BioSante Pharmaceuticals has been awarded a $150,000 Small Business Innovation Research grant from the National Institutes of Health to support the company's development of formulations for the pulmonary delivery of interferon alpha (IFN-a) using its proprietary calcium phosphate nanoparticulate (CaP) technology.
The new grant will be used to fund product development for IFN-a formulated with CaP particles for administration via inhalation. The desired outcome is safe and effective treatment of hepatitis B and C. An inhaled product may allow for convenient self-treatment, which would be an improvement over the current injectable IFN-a, the company said, noting that Tulin Morcol, director of preclinical development for BioSante, will serve as the principal investigator.
Dr Morcol added: "our advanced CaP technology for inhaled drugs (BioAir) not only allows non-invasive delivery of large-molecule drugs, but also may substantially reduce the size and frequency of dosing required." He noted that this innovative technology is also being developed for topical/transdermal delivery of large proteins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze